Trial Profile
A phase I multicenter, randomized, double-blind, placebo-controlled trial to evaluate the safety and immunogenicity of an HIV CTL multi-epitope peptide vaccine formulated with RC529-SE and GM-CSF given to HIV-1 positive adults on stable HAART.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs HIV vaccine (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions
- Sponsors Wyeth
- 08 Nov 2006 Status change
- 05 Dec 2005 New trial record.